<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906109</url>
  </required_header>
  <id_info>
    <org_study_id>DA2803_BE_I</org_study_id>
    <nct_id>NCT04906109</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 2x2 Crossover Study to Compare the Safety/Tolerability and Pharmacokinetics Between and DA-2803 and Vemlidy® After Meal in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, single dose, crossover study to evaluate the&#xD;
      pharmacokinetics, safety and tolerability of DA-2803 in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of ninety-six (96), following treatments are administered dosing in each&#xD;
      period and wash-out period is a minimum of 14 days.&#xD;
&#xD;
      Reference drug: Vemlidy Tab. / Test drug: DA-2803 Tab. Pharmacokinetic blood samples are&#xD;
      collected up to 72hrs. The pharmacokinetic characteristics and safety are assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of DA-2803, Vemlidy</measure>
    <time_frame>pre-dose(0 hour), 0.08, 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hour</time_frame>
    <description>Area under the DA-2803/Vemlidy concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of DA-2803, Vemlidy</measure>
    <time_frame>pre-dose(0 hour), 0.08, 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hour</time_frame>
    <description>The maximum DA-2803/Vemlidy concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Reference-Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test-Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemlidy Tab</intervention_name>
    <description>1T</description>
    <arm_group_label>Reference-Test</arm_group_label>
    <arm_group_label>Test-Reference</arm_group_label>
    <other_name>Reference</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-2803 Tab</intervention_name>
    <description>1T</description>
    <arm_group_label>Reference-Test</arm_group_label>
    <arm_group_label>Test-Reference</arm_group_label>
    <other_name>Test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers, aged between ≥ 19 and ≤ 45 years old at the time of&#xD;
             screening.&#xD;
&#xD;
          -  Calculated body mass index (BMI) of ≥ 18.0 and ≤ 28.0 kg/m2&#xD;
&#xD;
               -  BMI = Weight(kg)/ Height(m)2&#xD;
&#xD;
          -  Individuals who agreed proper contraception during the study and did consent to not&#xD;
             donation of sperm and ovum before the termination of study&#xD;
&#xD;
          -  Individuals who voluntary decide to participate and agrees in writing to comply with&#xD;
             the precautions after hearing and fully understanding the detailed explanation of this&#xD;
             clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant and sever active cardiovascular,&#xD;
             respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrine, immune,&#xD;
             dermatologic, neurologic, or psychiatric disorder.&#xD;
&#xD;
          -  Any medical history that may affect drug absorption, distribution, metabolism and&#xD;
             excretion.&#xD;
&#xD;
          -  Individuals who had history of hypersensitivity to Investigational drugs, derivative&#xD;
             drugs or others drugs(aspirin and antibiotics etc.)&#xD;
&#xD;
          -  Any clinically significant chronic medical illness.&#xD;
&#xD;
          -  Any genetic disease including galactose intolerance, Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption.&#xD;
&#xD;
          -  Individuals with one of the following laboratory test results in screening.&#xD;
&#xD;
               -  AST, ALT &gt; UNL (upper normal limit) x 1.5&#xD;
&#xD;
               -  Creatinine clearance ≤ 60 mL/min&#xD;
&#xD;
               -  Positive test results at HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL.&#xD;
&#xD;
          -  Use of any prescription drugs and herbal preparations within 14 days prior to study&#xD;
             drug administration and use of over-the-counter medications within 10 days prior to&#xD;
             study drug administration.&#xD;
&#xD;
          -  Individuals who cannot eat standard meal provided from clinical trial center.&#xD;
&#xD;
          -  Donation of blood within 60 days prior to study drug administration or apheresis&#xD;
             within 30 days prior to the first IP administration.&#xD;
&#xD;
          -  Individuals who had received a blood transfusion within 60 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  Exposure to any investigational drug within 6 months prior to the first IP&#xD;
             administration.&#xD;
&#xD;
          -  Individuals taking any drugs inducing or inhibiting drug metabolizing enzymes&#xD;
             including barbiturates within 30 days prior to the first IP administration.&#xD;
&#xD;
          -  Individuals who had drinking (alcohol &gt; 21unit/week) within 14 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  Heavy smoking (more than 10 cigarettes/day) within 14 days prior to screening.&#xD;
&#xD;
          -  Subjects having been deemed inappropriate for the trial as determined by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyun-Seop Bae, Professor</last_name>
    <phone>+82-2-3010-4611</phone>
    <email>ksbae@acp.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Kyun-Seop Bae, Professor</last_name>
      <phone>+82-2-3010-4611</phone>
      <email>ksbae@acp.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

